ALXO Q1 2025 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena

ALXOALX Oncology Holdings Inc.

$112M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$32M

Net Income

-$31M

EPS (Diluted)

$-0.58

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$121M

Total Liabilities

$33M

Stockholders' Equity

$88M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$214,000	+100.0%
Operating Income	-$32M	-$38M	+15.7%
Net Income	-$31M	-$36M	+13.6%